Compare

Oruka Therapeutics, Inc. vs Vanda Pharmaceuticals Inc. vs Theravance Biopharma, Inc. vs Rhythm Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Oruka Therapeutics, Inc. ORKA	Vanda Pharmaceuticals Inc. VNDA	Theravance Biopharma, Inc. TBPH	Rhythm Pharmaceuticals, Inc. RYTM
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	$216.10M	$107.46M	$189.76M
Revenue growth (YoY)	n/a	+8.7%	+66.9%	+45.8%
Gross margin	n/a	n/a	n/a	89.7% (computed)
Operating margin	n/a	-70.0%	-3.4%	-101.2%
Net margin	n/a	-102.0%	98.5%	-103.6%
Net income	-$105.43M	-$220.47M	$105.89M	-$196.54M
EPS (Diluted)	n/a	-$3.74	$2.06	-$3.11
Operating cash flow	-$88.21M	-$109.44M	$238.54M	-$115.67M
Free cash flow	-$88.42M	-$110.44M	$238.50M	-$116.63M
Cash & equivalents	$46.94M	$84.85M	$167.81M	$54.30M
Total assets	$488.62M	$488.95M	$485.57M	$480.20M
Total liabilities	$16.69M	$161.76M	n/a	$210.17M
Shareholders' equity	$471.93M	$327.19M	$296.72M	$139.07M
Return on year-end equity	-22.3%	-67.4%	35.7%	-141.3%
Shares outstanding	48.72M	59.10M	51.07M	67.21M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Oruka Therapeutics, Inc.	Vanda Pharmaceuticals Inc.	Theravance Biopharma, Inc.	Rhythm Pharmaceuticals, Inc.
Latest	$0 Ended 2023-12-31	$216.10M Ended 2025-12-31	$107.46M Ended 2025-12-31	$189.76M Ended 2025-12-31
1 year earlier	$0 Ended 2022-12-31	$198.77M Ended 2024-12-31	$64.38M Ended 2024-12-31	$130.13M Ended 2024-12-31
2 years earlier	$0 Ended 2021-12-31	$192.64M Ended 2023-12-31	$57.42M Ended 2023-12-31	$77.43M Ended 2023-12-31
3 years earlier	$0 Ended 2020-12-31	$254.38M Ended 2022-12-31	$51.35M Ended 2022-12-31	$23.64M Ended 2022-12-31
4 years earlier	$0 Ended 2019-12-31	$268.68M Ended 2021-12-31	$55.31M Ended 2021-12-31	$3.15M Ended 2021-12-31